Norges Bank Invests $76.20 Million in Lantheus Holdings, Inc. $LNTH

Norges Bank bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,144,955 shares of the medical equipment provider’s stock, valued at approximately $76,197,000. Norges Bank owned approximately 1.73% of Lantheus as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Trust Inc. raised its position in shares of Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 230 shares in the last quarter. Farther Finance Advisors LLC increased its position in Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares during the period. Resona Asset Management Co. Ltd. increased its position in Lantheus by 35.7% during the fourth quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 292 shares during the period. Verdence Capital Advisors LLC increased its position in Lantheus by 3.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider’s stock worth $563,000 after buying an additional 310 shares during the period. Finally, ProShare Advisors LLC increased its position in Lantheus by 2.4% during the fourth quarter. ProShare Advisors LLC now owns 14,911 shares of the medical equipment provider’s stock worth $992,000 after buying an additional 355 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on LNTH. Citizens Jmp lifted their price target on Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Truist Financial reaffirmed a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Trading Down 1.8%

Shares of LNTH stock opened at $100.98 on Friday. The business’s 50 day moving average is $88.01 and its two-hundred day moving average is $74.96. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $104.00. The company has a market capitalization of $6.57 billion, a P/E ratio of 24.33 and a beta of -0.03. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the firm posted $1.53 EPS. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts forecast that Lantheus Holdings, Inc. will post 4.42 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.